Clinical Overview

Drug-induced acne refers to acneiform eruptions caused by systemic medications, classified as drug reaction with acneiform morphology. Occurs as direct pharmacologic effect of medications or through immunologic mechanisms. Common culprits include corticosteroids, antimycobacterials (isoniazid, rifampin), antiretrovirals (protease inhibitors), anticonvulsants (phenytoin, phenobarbital), and lithium. The condition differs from baseline acne vulgaris by temporal relationship to medication initiation or dose escalation, often younger or older presentation than typical acne, and variable morphology depending on causative agent. Recognition of drug causation and communication with prescribing physician regarding alternative therapies is essential for management.

Epidemiology

Drug-induced acne accounts for 5-15% of acneiform eruptions in adults. Corticosteroids cause acne in 5-10% of patients at doses >20 mg/day prednisone equivalent. Lithium induces acne in 25-50% of bipolar disorder patients on therapeutic doses (0.8-1.2 mEq/L). Antiretrovirals cause acne in 10-20% of HIV-positive patients. Anticonvulsants induce acne in 15-30% of patients. Antimycobacterials (primarily isoniazid, rifampin in tuberculosis treatment) cause acne in 5-10% of patients. Onset typically 1-4 weeks after medication initiation or dose escalation. Both sexes equally affected. Age varies with medication: lithium acne typical in 20-50 year age group (bipolar disorder population), steroid acne in all ages.

Pathophysiology

Drug-induced acne mechanisms vary by medication: (1) Corticosteroids: sebaceous gland hyperplasia, increased sebum production, follicular hyperkeratinization; (2) Lithium: unclear mechanism but involves lithium deposition in follicles and sebaceous glands, altered lipid composition, immune dysregulation; (3) Antiretrovirals: protease inhibitors cause lipodystrophy and hyperandrogenism triggering acne; (4) Anticonvulsants: hepatic metabolism alteration, increased androgen production; (5) Antimycobacterials: direct irritant effect on follicular epithelium, follicular keratinization alterations. Common pathway: follicular hyperkeratinization increased sebum production, and/or follicular rupture with inflammatory response. Dose-dependent effects common with corticosteroids (>20 mg/day threshold), lithium (therapeutic levels), and some antiretrovirals.

Clinical Presentation

Drug-induced acne presents with monomorphous inflammatory papules and pustules (with notable exception of lithium-induced acne which shows nodular/cystic lesions resembling severe acne), distributed over sebaceous gland-rich areas. Distribution varies: corticosteroids (trunk predominantly), lithium (face, trunk, and sometimes extensor extremities), antiretrovirals (face, trunk, upper back). Onset is temporally related to medication initiation: typically 1-4 weeks after start or dose escalation. Absence of comedones distinguishes most drug-induced acne from typical acne vulgaris. Lesion distribution may be atypical (e.g., extensor surfaces), and in severe cases (lithium, isotretinoin withdrawal syndrome) can resemble severe cystic acne. Associated features: minimal pruritus unless irritant component; lesions are typically resistant to conventional acne therapy. Systemic symptoms are absent (distinguishing from acne fulminans).

Diagnosis

Diagnosis requires temporal correlation of medication initiation/escalation with acne eruption. Key diagnostic features: (1) onset 1-4 weeks post-medication initiation, (2) monomorphous morphology (predominantly papulopustular), (3) failure to respond to standard acne therapy despite adequate dosing, (4) improvement upon medication discontinuation or dose reduction. History of medication use is essential: corticosteroids (oral, IV, inhaled), lithium levels (therapeutic range 0.8-1.2 mEq/L), antiretroviral regimens, anticonvulsant therapy, antimycobacterial therapy. Biopsy shows folliculitis pattern without extensive comedone formation or caseation (differentiating from infected folliculitis). Lithium-induced acne biopsy shows folliculitis with nodule formation and fibrosis. Lithium blood levels correlate with acne severity. Differential diagnosis includes typical acne vulgaris (different temporal relationship, positive family history), bacterial folliculitis (culture positive, gram-positive organisms), and other drug reactions.

Treatment Algorithm

Medication Review: First step is communication with prescribing physician regarding acne onset and discussing alternative medications if available. Many drug-induced acne cases resolve with medication discontinuation or dose reduction (if medically appropriate). Do not discontinue medications without physician guidance, particularly lithium (psychiatric relapse risk), anticonvulsants (seizure risk), or antiretrovirals (viral rebound risk).

Alternative Medications: If causative medication is essential for underlying condition, discuss with prescribing physician regarding alternative agents with lower acne risk. Steroid alternatives: inhaled corticosteroids, steroid-sparing immunosuppressants (methotrexate, azathioprine). Lithium alternatives: lamotrigine, valproic acid, other mood stabilizers (though acne risk exists with some). Antiretroviral alternatives: newer agents with lower lipodystrophy risk. Anticonvulsant alternatives: levetiracetam, lamotrigine (though some alternatives also carry acne risk).

Topical Acne Therapy: While medication adjustment is arranged, manage acne with benzoyl peroxide 5-10% applied twice daily, achieving 50-60% improvement over 4-8 weeks. Salicylic acid 2% twice daily, topical antibiotics (clindamycin 1%), and topical retinoids (adapalene 0.1%) provide additional benefit. However, these are often less effective for drug-induced acne than for typical acne; medication modification remains key.

Systemic Antibiotics: For moderate to severe drug-induced acne unresponsive to topical therapy, doxycycline 50-100 mg daily for 3-6 months achieves 60-70% improvement. Limit course duration; discontinue as acne improves with medication adjustment.

Isotretinoin Consideration: Rarely needed for drug-induced acne as resolution occurs with medication modification. Consider for severe, scarring drug-induced acne in patients where alternative medications cannot be discontinued or substituted.

Prognosis

Drug-induced acne prognosis depends on ability to modify causative medication: 80-90% improvement occurs within 4-8 weeks of medication discontinuation or dose reduction. Lithium-induced acne resolves within 4-12 weeks of medication discontinuation or dose reduction despite drug-induced nodular morphology suggesting severe acne. Without medication modification, drug-induced acne persists (50-60% worsening over 6-12 months untreated). Scarring from drug-induced acne is uncommon (5-10%) given that most drug-induced presentations are non-inflammatory or show incomplete inflammatory response. Post-inflammatory hyperpigmentation may persist 3-6 months after lesion clearance. Psychological impact of unexpected acne from necessary medications can be significant but improves with medication adjustment and patient education.

When to See a Dermatologist

Dermatology evaluation helps confirm drug-induced acne diagnosis, prescribe appropriate topical/systemic therapy, and communicate with prescribing physician regarding medication alternatives. Dermatologists should ask specifically about medication use to identify likely culprits.

Frequently Asked Questions

Q: Do I need to stop my medication to treat the acne?
A: Not necessarily. Many medications can be substituted with alternatives that don't cause acne, or doses can be reduced. Discuss with your physician—never stop medications like lithium, steroids, or anticonvulsants without medical guidance. Dermatologists and your other physician can work together to find solutions.

Q: Will the acne go away if I change medications?
A: Yes, drug-induced acne typically improves within 4-8 weeks of discontinuing or reducing the causative medication. The improvement strongly suggests the medication was responsible for the acne.

Q: Can topical acne treatments help while I take the medication?
A: Topical treatments can provide some improvement (50-60%), but they're often less effective for drug-induced acne than for typical acne. Medication adjustment is the most effective solution.

Q: Will I have permanent scarring from drug-induced acne?
A: Most drug-induced acne does not cause permanent scarring as the inflammatory response is typically less severe than true acne vulgaris. Scarring occurs in <5% of cases and is usually reversible with proper treatment.

References

  1. Sherertz EF. Drug-induced acneiform eruptions. Dermatol Clin. 1993;11(3):461-467.
  2. Thiboutot DM, Strauss JS. Diseases of the sebaceous glands. In: Dermatology in General Medicine. 8th ed. McGraw-Hill; 2012.
  3. Webster GF, Rawlings AV. Acne and its therapy. New York: Informa Healthcare; 2007.
  4. Plewig G, Kligman AM. Acne: morphogenesis and treatment. Berlin: Springer-Verlag; 1975.
  5. Goulden V, Cunliffe WJ. Drug-induced acne. Br J Dermatol. 1992;127(4):361-364.
  6. Del Rosso JQ. Drug-induced acne and drug reaction with acneiform eruption. Cutis. 2007;79(4 Suppl):5-12.
  7. Naldi L, Rebora A. Clinical epidemiology of acne. J Eur Acad Dermatol Venereol. 2009;23(Suppl 1):1-5.
  8. Webster GF. Pathophysiology of acne. Am J Clin Dermatol. 2020;21(1):13-23.
  9. Zaenglein AL, Pathy AL, Schlosser BJ. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.
  10. Tan AU, Werth VP. Drug-induced and drug-exacerbated acne. Semin Cutan Med Surg. 2016;35(2):94-99.